Telix Pharmaceuticals H1 Earnings Call Highlights

Strong first-half financial performance: Telix reported revenue of $477 million, up 22% year over year, while EBITDA surged 146% to $52 million and net profit reached $38 million. The company is tracking toward the upper end of its AUD 950 million–AUD 970 million full-year revenue guidance.

Imaging portfolio continues expanding: Precision medicine sales rose 27% to approximately AUD 390 million, driven by Gozellix and Illuccix. Telix has launched or begun launching its PSMA imaging products in 24 countries, with further regulatory submissions and reviews underway in China, Japan, the U.S. and Europe.

Pipeline advances support future growth: The Phase III BiPASS study is nearing its enrollment target and could significantly expand the PSMA imaging market if it reduces unnecessary prostate biopsies. Telix also progressed multiple therapeutic programs, including TLX591, TLX597 and TLX101, while increasing 2026 R&D guidance to AUD 230 million–AUD 270 million.

Telix Pharmaceuticals NASDAQ: TLX reported first-half 2026 revenue of $477 million, up 22% from the prior-year period, as demand for its precision medicine imaging products continued to grow. The company said EBITDA increased 146% year over year to $52 million, while net profit after tax rose to $38 million.

Managing Director and Group CEO Dr. Christian Behrenbruch said the company generated approximately AUD 390 million in precision medicine sales, a 27% increase from a year earlier, driven by the launch of Gozellix and continued growth in Illuccix. Telix said it is tracking toward the upper end of its full-year revenue guidance of AUD 950 million to AUD 970 million.

Group CFO Darren Smith said Telix’s precision medicine business generated gross margins of 65%, up 1 percentage point year over year. Consolidated gross margin improved 2 percentage points to 55%, he said. The company increased its cash balance to $252 million following a refinancing of its convertible bonds. Smith said Telix is prioritizing reinvestment in development programs rather than maximizing near-term earnings. Research and development spending represented 26% of revenue in the first half. Telix updated its 2026 R&D guidance to AUD 230 million to AUD 270 million, citing additional investment in development programs and its collaboration with Regeneron. Precision medicine EBITDA rose 26% year over year to AUD 132 million. Telix Manufacturing Solutions, including RLS, generated AUD 89 million in third-party revenue, up 10% year over year. Internal revenue distributed through RLS increased 70% to AUD 57 million, making RLS Telix’s second-largest distributor of its products, according to Smith. Telix said it continues to invest in manufacturing and distribution capacity at facilities in Seneffe, Yokohama and selected RLS sites. The investments include clean-room capacity, cyclotrons and capabilities needed to dispense lutetium therapeutic drugs.

Kevin Richardson, CEO of Telix Precision Medicine, said the company’s prostate-specific membrane antigen, or PSMA, imaging portfolio has gained unit and revenue market share for 16 consecutive quarters. Revenue from the portfolio totaled $202 million in the second quarter, up 9% sequentially, following $186 million in the first quarter. Richardson said Telix’s two-product strategy, centered on Illuccix and Gozellix, was designed to serve different customer segments. He said the products’ clinical characteristics, service reliability, ordering process, pricing consistency and physician education efforts have supported adoption. Telix has launched or initiated launches of its...